Gobbi C - Search Results

1

Hydrocephalus during natalizumab treatment.

Zecca C, Städler C, Gobbi C. Zecca C, et al. Among authors: gobbi c. Neurol Sci. 2010 Oct;31(5):635-7. doi: 10.1007/s10072-010-0282-9. Epub 2010 May 8. Neurol Sci. 2010. PMID: 20454819

2

Recurrent myelitis associated with herpes simplex virus type 2.

Gobbi C, Tosi C, Städler C, Merenda C, Bernasconi E. Gobbi C, et al. Eur Neurol. 2001;46(4):215-8. doi: 10.1159/000050808. Eur Neurol. 2001. PMID: 11721130 No abstract available.

3

Ocular toxoplasmosis during natalizumab treatment.

Zecca C, Nessi F, Bernasconi E, Gobbi C. Zecca C, et al. Among authors: gobbi c. Neurology. 2009 Oct 27;73(17):1418-9. doi: 10.1212/WNL.0b013e3181bd114f. Epub 2009 Sep 23. Neurology. 2009. PMID: 19776379 No abstract available.

4

Tolerability and acceptance of prolonged low/delayed mitoxantrone regimens in patients with worsening multiple sclerosis.

Zecca C, Petrini L, Limoni C, Staedler C, Gobbi C. Zecca C, et al. Among authors: gobbi c. Eur Neurol. 2011;65(1):40-5. doi: 10.1159/000323013. Epub 2010 Dec 22. Eur Neurol. 2011. PMID: 21196739

5

Diffusion-weighted imaging in acute demyelinating myelopathy.

Zecca C, Cereda C, Wetzel S, Tschuor S, Staedler C, Santini F, Nadarajah N, Bassetti CL, Gobbi C. Zecca C, et al. Among authors: gobbi c. Neuroradiology. 2012 Jun;54(6):573-8. doi: 10.1007/s00234-011-0907-6. Epub 2011 Jul 9. Neuroradiology. 2012. PMID: 21743997 Free article.

6

Percutaneous posterior tibial nerve stimulation as an effective treatment of refractory lower urinary tract symptoms in patients with multiple sclerosis: preliminary data from a multicentre, prospective, open label trial.

Gobbi C, Digesu GA, Khullar V, El Neil S, Caccia G, Zecca C. Gobbi C, et al. Mult Scler. 2011 Dec;17(12):1514-9. doi: 10.1177/1352458511414040. Epub 2011 Jul 14. Mult Scler. 2011. PMID: 21757534 Clinical Trial.

7

Chronic cerebrospinal venous insufficiency (CCSVI) and multiple sclerosis (MS): a critical review.

Zecca C, Gobbi C. Zecca C, et al. Among authors: gobbi c. CNS Neurol Disord Drug Targets. 2011 Sep 1;10(6):757-61. doi: 10.2174/187152711797247786. CNS Neurol Disord Drug Targets. 2011. PMID: 21838669 Review.

8

Mutant superoxide dismutase-1 indistinguishable from wild-type causes ALS.

Synofzik M, Ronchi D, Keskin I, Basak AN, Wilhelm C, Gobbi C, Birve A, Biskup S, Zecca C, Fernández-Santiago R, Kaugesaar T, Schöls L, Marklund SL, Andersen PM. Synofzik M, et al. Among authors: gobbi c. Hum Mol Genet. 2012 Aug 15;21(16):3568-74. doi: 10.1093/hmg/dds188. Epub 2012 May 16. Hum Mol Genet. 2012. PMID: 22595972

9

Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients.

Zecca C, Yawalkar N, Gobbi C. Zecca C, et al. Among authors: gobbi c. Patient Prefer Adherence. 2012;6:565-7. doi: 10.2147/PPA.S33727. Epub 2012 Aug 8. Patient Prefer Adherence. 2012. PMID: 22927749 Free PMC article.

10

Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.

Cereda CW, Zecca C, Mazzucchelli L, Valci L, Staedler C, Bassetti CL, Gobbi C. Cereda CW, et al. Among authors: gobbi c. Mult Scler. 2013 May;19(6):820-3. doi: 10.1177/1352458512461969. Epub 2012 Oct 15. Mult Scler. 2013. PMID: 23069873

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

288 results

Search Page

Filters